Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by snrkidon Apr 22, 2009 8:28pm
364 Views
Post# 15937769

RE: Snrkid says

RE: Snrkid saysI was here.  I also wittnessed Roche stalling all trials with ISA247 from the time Isotechnika itroduced TAFA molecule.  It was haailed at the time to be replacement to CellCept, better and non toxic version.  TAFA as you know is presently also in human trials by our partners.

Isotechnika had no choice but get transplant separated which looking back was brilliant move. You may have trust in Roche, I don't

snrkid.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities